Detalles de la búsqueda
1.
Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION Network.
Clin Infect Dis
; 78(3): 746-755, 2024 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37972288
2.
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024.
MMWR Morb Mortal Wkly Rep
; 73(12): 271-276, 2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38547037
3.
Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network.
J Infect Dis
; 228(2): 185-195, 2023 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36683410
4.
Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023.
J Infect Dis
; 2023 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38041853
5.
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
MMWR Morb Mortal Wkly Rep
; 72(21): 579-588, 2023 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37227984
6.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
MMWR Morb Mortal Wkly Rep
; 71(53): 1637-1646, 2023 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36921274
7.
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
MMWR Morb Mortal Wkly Rep
; 71(29): 931-939, 2022 Jul 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35862287
8.
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
MMWR Morb Mortal Wkly Rep
; 71(13): 495-502, 2022 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35358170
9.
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
MMWR Morb Mortal Wkly Rep
; 71(42): 1335-1342, 2022 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36264840
10.
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(4): 139-145, 2022 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35085224
11.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
MMWR Morb Mortal Wkly Rep
; 71(5152): 1616-1624, 2022 Dec 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36580430
12.
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
MMWR Morb Mortal Wkly Rep
; 70(44): 1553-1559, 2021 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34735426
13.
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.
Am J Transplant
; 23(7): 1062-1076, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37394267
14.
Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021.
Am J Transplant
; 22(1): 306-314, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34967121
15.
Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.
Influenza Other Respir Viruses
; 18(3): e13269, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494192
16.
Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study.
Lancet Reg Health Am
; 23: 100530, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37333688
17.
Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
Vaccine
; 41(37): 5424-5434, 2023 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37479609
18.
Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
JAMA Netw Open
; 6(3): e232598, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36920396
19.
Fluphenazine release from biodegradable microparticles: characterization and modelling of release.
J Microencapsul
; 26(5): 403-10, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-18785053
Resultados
1 -
19
de 19
1
Próxima >
>>